Quantcast

Latest Gene therapy Stories

2014-08-13 08:26:49

SAN DIEGO, Aug. 13, 2014 /PRNewswire/ -- Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional...

2014-08-11 23:01:33

Darst and Landes – both of whom lost mothers to cancer – will connect with a younger demographic. Stamford, CT (PRWEB) August 11, 2014 Alliance for Cancer Gene Therapy, Inc. (ACGT) – the nation’s only nonprofit dedicated exclusively to cell and gene therapies for cancer – has announced that David Darst and Alexandra Landes have joined the foundation’s Board of Directors. Both Darst and Landes lost their mothers to cancer and share a commitment to uncovering innovative methods...

2014-08-11 16:28:00

Oncothyreon to Leverage Alpine's Protocell Technology to Enable Targeted Delivery of Molecular Therapeutics for Serious Diseases Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately...

2014-07-21 08:29:00

LONDON, July 21, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Cell Culture Market by Equipment (Bioreactor, Incubator, Centrifuge), by Reagent (Media, Sera, Growth Factors, Serum Free Media), by Application (Cancer Research, Gene Therapy, Drug Development, Vaccine Production, Toxicity Testing) - Global Forecast to...

2014-07-10 12:45:13

Salk Institute New results ease previous concerns that gene-editing techniques—used to develop therapies for genetic diseases—could add unwanted mutations to stem cells. The ability to switch out one gene for another in a line of living stem cells has only crossed from science fiction to reality within this decade. As with any new technology, it brings with it both promise—the hope of fixing disease-causing genes in humans, for example—as well as questions and safety concerns....

2014-07-07 12:28:59

Engineered Cells Known As CTL019 Are the First Therapy of Their Kind to Obtain Designation PHILADELPHIA, July 7, 2014 /PRNewswire/ -- A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The investigational therapy, known as CTL019, is the first personalized cellular therapy for the...

2014-06-25 23:00:47

Eighth annual Greenwich-Stamford Open Water Swim unites Connecticut residents to find a cure. Stamford, CT (PRWEB) June 25, 2014 Over 300 volunteers from across Connecticut and beyond came together on Saturday, June 21 at the eighth-annual Greenwich-Stamford Swim Across America event, raising over $300,000 to benefit Stamford’s Alliance for Cancer Gene Therapy (ACGT) in the fight against cancer. Participants spent the morning swimming half-mile, 1.5-mile or three-mile courses in the...

2014-06-24 08:32:14

Pioneering Angiogenic Gene Therapy for the Potential Treatment of Millions of Patients with Heart Disease Worldwide SAN DIEGO, June 24, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(®) Ad5FGF-4, Cardium Therapeutics' angiogenic gene...

2014-06-23 08:27:25

LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, have entered into a collaboration for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. "Bayer is a worldwide leader in the treatment of hemophilia A and we are highly committed to advancing innovative treatment options for...

2014-06-19 08:28:26

RICHMOND, Calif., June 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's Board of Directors. Ms. Parker, who founded and served as President and CEO of Targeted Genetics Corporation, brings more than 30 years of experience in the biotechnology industry, including 16 years of specific experience in cell and gene therapy. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO "We are very pleased to...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related